Research
Hormonal
Total activation of PPAR-gamma (e.g., via rosiglitazone) can be detrimental to liver histology by promoting hepatic lipogenesis, whereas partial activation (e.g., via telmisartan or pioglitazone) improves insulin sensitivity and reduces steatosis without the harmful lipid accumulation.
Not all diabetes medications that target PPAR-gamma work the same way for fatty liver. Total activation might increase liver fat, so partial activation strategies (like those with telmisartan or pioglitazone) are often preferred to improve insulin sensitivity without worsening liver fat.
ModerateQualifiesMEDIUM confidence
Total PPAR-gamma activation by rosiglitazone counters insulin resistance, but do not manage to reduce NAFLD in HF mouse models... the upregulation of lipogenesis results in obesity, increased hepatic triglycerides and the maintenance of NAFLD.
Why this rating
Supported by murine models and human trials (FLIRT, PIVENS), but results on histology are mixed.
Source
Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease
Vanessa Souza‐Mello · World Journal of Hepatology · 2015
DOI 10.4254/wjh.v7.i8.1012
narrative_reviewCited 179×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- High intake of simple carbohydrates (sucrose, fructose) and high-fat diets disrupt PPAR-alpha and PPAR-gamma balance, leading to reduced beta-oxidation and increased lipogenesis, which drives NAFLD progression.Good
- Activation of PPAR-alpha using agonists like fenofibrate or fish oil reduces hepatic steatosis and insulin resistance in NAFLD by upregulating mitochondrial beta-oxidation and reducing de novo lipogenesis.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →